Dr. Hammers on Study of HyperAcute Renal Immunotherapy in RCC

Hans Hammers, MD, PhD
Published: Thursday, Feb 16, 2017



Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses HyperAcute Renal (HAR) immunotherapy in patients with renal cell carcinoma (RCC).

In a phase I study of alpha-1, 3-galactosyltransferase-expressing allogeneic RCC immunotherapy, patients with metastatic RCC were given injections of HAR for 4 weeks (150 x106 cells/300 x106 cells intradermally). This was followed by 10 weeks of bi-weekly injections.

HAR was well tolerated in this population, says Hammers, and RCC was deemed an appropriate tumor type to target with combination immunotherapy.
 

<<< View more from the 2017 Genitourinary Cancers Symposium



Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses HyperAcute Renal (HAR) immunotherapy in patients with renal cell carcinoma (RCC).

In a phase I study of alpha-1, 3-galactosyltransferase-expressing allogeneic RCC immunotherapy, patients with metastatic RCC were given injections of HAR for 4 weeks (150 x106 cells/300 x106 cells intradermally). This was followed by 10 weeks of bi-weekly injections.

HAR was well tolerated in this population, says Hammers, and RCC was deemed an appropriate tumor type to target with combination immunotherapy.
 

<<< View more from the 2017 Genitourinary Cancers Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x